413
Views
39
CrossRef citations to date
0
Altmetric
Original Articles

Long-term Efficacy of Interferon in Severe Uveitis Associated with Behçet Disease

, MD, , MD, , MD, , MD, , MD, PhD & , MD, PhD
Pages 76-84 | Received 14 Feb 2016, Accepted 22 Jun 2016, Published online: 19 Aug 2016
 

ABSTRACT

Purpose: To retrospectively assess the frequency of ocular relapse and the possibility of long-term remission in patients treated with interferon (IFN) for severe uveitis associated with Behçet disease.

Methods: All patients were treated with an initial dosage of 3 million IU IFN three times a week. The main outcome measure was the number of relapses per person per year before, during, and after IFN treatment.

Results: Of 36 patients (67 eyes), 31 (86.1%) responded to IFN. The mean follow-up was 8.19 years. Twenty-one out of 36 patients discontinued IFN and 76% of these have not relapsed within 5.05 years after discontinuation. The mean relapse per person per year decreased significantly from 1.39 to 0.0496 (p = 1.82×10−10) during the treatment period and remained at 0.057 relapses per person per year after IFN discontinuation.

Conclusion: IFN efficiently decreases the relapse rate and seems to permit long-term remission even after discontinuation.

DECLARATION OF INTEREST

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.